Name: UMIN ID:
Unique ID issued by UMIN | UMIN000004686 |
---|---|
Receipt number | R000005575 |
Scientific Title | A phase II study of Carboplatin+Pemetrexed +Bevacizumab for gefitinib refractory NSCLC patients with mutated EGFR |
Date of disclosure of the study information | 2010/12/08 |
Last modified on | 2019/06/21 20:44:17 |
No. | Disposal | Last modified on | Item of update | |
---|---|---|---|---|
1 | Insert | 2010/12/08 13:08:27 | ||
2 | Update | 2010/12/08 13:49:38 | Institutions |
|
3 | Update | 2011/12/08 09:03:06 | Post marketing survey by drug manufacture etc., specified by Japanese law. |
|
4 | Update | 2014/05/21 13:49:37 | Email Name of person sending information Name of person sending information Address Address |
|
5 | Update | 2014/06/10 13:41:01 | Recruitment status |
|
6 | Update | 2015/05/29 13:59:34 | Division name Division name |
|
7 | Update | 2016/05/12 09:57:17 | Name of person sending information Name of person sending information Division name Division name TEL Name of primary person or sponsor Organization |
|
8 | Update | 2018/06/14 10:40:30 | Name of person sending information Name of person sending information TEL |
|
9 | Update | 2019/06/21 20:41:28 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Zip code Address Last name of contact person Last name of contact person Zip code Address Organization Organization Address Address Tel |
|
10 | Update | 2019/06/21 20:42:55 | URL releasing protocol URL related to results and publications Number of participants that the trial has enrolled Results Results Results date posted Baseline Characteristics Baseline Characteristics Participant flow Participant flow Adverse events Adverse events Outcome measures Outcome measures |
|
11 | Update | 2019/06/21 20:44:17 | Recruitment status Date of IRB |